细胞毒化疗药物不良反应支持治疗的指南进展及实践总结

王燕婷, 戴媛媛, 杨珺, 李国辉

中国药学杂志 ›› 2020, Vol. 55 ›› Issue (20) : 1726-1735.

PDF(6481 KB)
中国药学杂志
PDF(6481 KB)
中国药学杂志 ›› 2020, Vol. 55 ›› Issue (20) : 1726-1735. DOI: 10.11669/cpj.2020.20.012
论著

细胞毒化疗药物不良反应支持治疗的指南进展及实践总结

  • 王燕婷, 戴媛媛, 杨珺, 李国辉*
作者信息 +

Progress of Guidelines and Practice Summary for Supportive Care of Adverse Reactions Induced by Cytotoxic Chemotherapy Drugs

  • WANG Yan-ting, DAI Yuan-yuan, YANG Jun, LI Guo-hui*
Author information +
文章历史 +

摘要

目的 化疗在恶性肿瘤的治疗中仍占据重要位置,然而,细胞毒化疗药物的不良反应对治疗结局有较大影响,因此对药物不良反应进行支持治疗与化疗相比同等重要。笔者旨在对细胞毒类化疗药物常见不良反应的支持治疗策略进行指南进展的复习和实践总结。方法 采用描述性综述的方法。结果 根据最新的国内外指南和研究文献,结合肿瘤专科医院临床药师的实践经验,对细胞毒类化疗药物所致的常见不良反应以及目前普遍采用的相应支持治疗策略进行了分类总结。结论 细胞毒化疗药物不良反应的支持治疗措施已相对标准化,药师应完善自身的知识结构,在化疗药物的用药安全方面多下功夫,为促进临床合理用药贡献力量。

Abstract

OBJECTIVE Cytotoxic chemotherapeutics still occupy an important position in the treatment of malignant tumors. However, their adverse reactions have a great impact on the treatment outcome. Therefore, supportive care for the adverse drug reactions is as important as chemotherapy itself. To review and summarize the progress of the guidelines on supportive care for common adverse reactions of cytotoxic chemotherapy drugs. METHODS Descriptive literature review was used in this article. RESULTS Based on the latest domestic and international guidelines and research literature, together with the practical experience of clinical pharmacists in cancer-specialized hospitals, we summarized the common adverse reactions induced by cytotoxic chemotherapy drugs and the corresponding supportive care strategies. CONCLUSION Supportive care for adverse drug reactions have been relatively standardized. Pharmacists should strengthen their knowledge structure, pay more attention on the drug safety, in order to play a better role in promoting the rational use of antitumor drugs.

关键词

恶性肿瘤 / 细胞毒化疗药物 / 不良反应 / 支持治疗 / 药师

Key words

malignant tumor / cytotoxic chemotherapy drug / adverse drug reaction / supportive care / pharmacist

引用本文

EndNote

Ris (Procite)

Bibtex

导出引用
王燕婷, 戴媛媛, 杨珺, 李国辉. 细胞毒化疗药物不良反应支持治疗的指南进展及实践总结[J]. 中国药学杂志, 2020, 55(20): 1726-1735 https://doi.org/10.11669/cpj.2020.20.012
WANG Yan-ting, DAI Yuan-yuan, YANG Jun, LI Guo-hui. Progress of Guidelines and Practice Summary for Supportive Care of Adverse Reactions Induced by Cytotoxic Chemotherapy Drugs[J]. Chinese Pharmaceutical Journal, 2020, 55(20): 1726-1735 https://doi.org/10.11669/cpj.2020.20.012
中图分类号： R95   

参考文献

[1] BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6):394-424.
[2] The Lancet. GLOBOCAN 2018: counting the toll of cancer. Lancet, 2018, 392(10152):985.
[3] FENG R M, ZONG Y N, CAO S M, et al. Current cancer situation in China: good or bad news from the 2018 global cancer statistics?. Cancer Commun (Lond), 2019, 39(1):22.
[4] MULTINATIONAL ASSOCIATION OF SUPPORTIVE CARE IN CANCER. MASCC strategic plan, consensus on the core ideology of MASCC. . https://www. mascc. org/mascc-strategic-plan. Accessed on August 10, 2020.
[5] SHI H P, YU S Y, BA Y, et al. The scope, model and development of tumor supportive care. Elect J Metabol Nut Cancer(肿瘤代谢与营养),2018, 5(4):333-336.
[6] CANCER REHABILITATION AND PALLIATIVE COMMITTEE OF SHANGHAI ANTI-CANCER ASSOCIATION. Shanghai expert consensus on the whole-process management of chemotherapy-induced nausea and vomiting (2018 edition). China Oncol(中国癌症), 2018, 28(12):946-960.
[7] JIANG W Q, BA Y, FENG J F, et al. Chinese expert consensus on the prevention and treatment of nausea and vomiting related to chemotherapy (2019 edition). Chin J Front Med Sci(Electronic Version)(中国医药前沿), 2019, 11(11):16-26.
[8] NATIONAL COMPREHENSIVE CANCER NETWORK. NCCN clinical practice guidelines in oncology antiemesis 2020 version 1. . http://www.nccn.org/professionds/physician_gls/default.aspx.
[9] NATIONAL COMPREHENSIVE CANCER NETWORK. NCCN clinical practice guidelines in oncology antiemesis 2019 version 1. . http://www.nccn.org/professionds/physician_gls/default.aspx.
[10] US DEPARTMENT OF HEALTH AND HUMAN SERVICES. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. . https://ctep. cancer. gov/protocoldevelopment/ electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7. pdf.
[11] CANCER SUPPORTIVE CARE COMMITTEE AND CLINICAL CHEMOTHERAPY COMMITTEE OF CHIN ANTI-CANCER ASSOCIATION. A consensus on the clinical diagnosis, treatment, and prevention of chemotherapy-related anemia in China (2019 edition). Chin J Clin Oncol(中国肿瘤临床), 2019, 46(17):869-875.
[12] GUIDELINES WORKING COMMITTEE OF CHINESE SOCIETY OF CLINICAL ONCOLOGY. Guidelines for standardized management of neutropenia induced by chemotherapy and radiotherapy. Chin J Oncol(中华肿瘤), 2017, 39(11):868-878.
[13] CANCER SUPPORTIVE CARE COMMITTEE AND CLINICAL CHEMOTHERAPY COMMITTEE OF CHIN ANTI-CANCER ASSOCIATION. Consensus on the clinical diagnosis and treatment of chemotherapy-induced thrombocytopenia in China (2019 version). Chin J Clin Oncol(中国肿瘤临床), 2019, 46(18):923-929.
[14] SHI Y K, BA Y, FENG J F, et al. Chinese expert consensus on the properties of anthracyclines. Chin J Clin Oncol(中国肿瘤临床), 2018, 45(3):109-112.
[15] KUMAR S, MARFATIA R, TANNENBAUM S, et al. Doxorubicin-induced cardiomyopathy 17 years after chemotherapy. Tex Heart Inst J, 2012, 39(3):424-427.
[16] RYBERG M, NIELSEN D, CORTESE G, et al. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients. J Natl Cancer Inst, 2008, 100(15):1058-1067.
[17] CAI F, LUIS M, LIN X, et al. Anthracycline-induced cardiotoxicity in the chemotherapy treatment of breast cancer: preventive strategies and treatment. Mol Clin Oncol, 2019, 11(1):15-23.
[18] HU Z Q, YU W T, YAO W X, et al. Research progress on cardiotoxicity caused by antitumor drugs and its prevention and treatment measures. J China Pharm(中国药房), 2020, 31(2):250-256.
[19] ARMENIAN S H, LACCHETTI C, BARAC A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: american society of clinical oncology clinical practice guideline. J Clin Oncol, 2017, 35(8):893-911.
[20] VIRANI S A, DENT S, BREZDEN-MASLEY C, et al. Canadian cardiovascular society guidelines for evaluation and management of cardiovascular complications of cancer therapy. Can J Cardio, 2016, 32(7):831-841.
[21] VAN DALEN E C, CARON H N, DICKINSON H O, et al. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev, 2011(6):CD003917.
[22] CHINESE SOCIETY OF CLINICAL ONCOLOGY, HEMATOLOGY BRANCH OF CHINESE MEDICAL ASSOCIATION. Guidelines for prevention and treatment of cardiotoxicity of anthracyclines (2013 edition). Chin Clin Oncol(临床肿瘤学), 2013, 18(10):925-934.
[23] MLADENKA P, APPLOVA L, PATOCKA J, et al. Comprehensive review of cardiovascular toxicity of drugs and related agents. Med Res Rev, 2018, 38(4):1332-1403.
[24] ABDEL-QADIR H, ONG G, FAZELZAD R, et al. Interventions for preventing cardiomyopathy due to anthracyclines: a Bayesian network Meta-analysis. Ann Oncol, 2017, 28(3):628-633.
[25] CHALASANI N P, HAYASHI P H, BONKOVSKY H L, et al. ACG clinical guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol, 2014, 109(7):950-967.
[26] HASSAN A, FONTANA R J. The diagnosis and management of idiosyncratic drug-induced liver injury. Liver Int, 2019, 39(1):31-41.
[27] DRUG-INDUCED LIVER DISEASE STUDY GROUP OF CHINESE MEDICAL ASSOCIATION. Guidelines for the management of drug-induced liver injury. Chin J Viral Dis(中国病毒病杂志), 2015, 5(5):321-341.
[28] YU S Y, YAO Y. Expert Consensus on Prevention and Treatment of Antitumor Drugs-Related Liver Injury(肿瘤药物相关性肝损伤防治专家共识). Beijing: Peking Union Medical College Press, 2014.
[29] PATEL T, TARUN T, HUDHUD D, et al. Novel use of N-acetylcysteine in management of tyrosine kinase inhibitor induced acute liver injury. Cureus, 2019, 11(11):e6251.
[30] JAISWAL P, ATTAR B M, YAP J E, et al. Acute liver failure with amiodarone infusion: a case report and systematic review. J Clin Pharm Ther, 2018, 43(1):129-133.
[31] MALYSZKO J, KOZLOWSKA K, KOZLOWSKI L, et al. Nephrotoxicity of anticancer treatment. Nephrol Dial Transplant, 2017, 32(6):924-936.
[32] HORIE S, OYA M, NANGAKU M, et al. Guidelines for treatment of renal injury during cancer chemotherapy 2016. Clin Exp Nephrol, 2018, 22(1):210-244.
[33] ZHOU J C. Practice of Medical Oncology Treatment(实用肿瘤内科治疗). Beijing: Beijing Science and Technology Press, 2016.
[34] CRONA D J, FASO A, NISHIJIMA T F, et al. A systematic review of strategies to prevent cisplatin-induced nephrotoxicity. Oncologist, 2017, 22(5):609-619.
[35] WANG M. Research progress in the mechanism, early diagnosis, prevention and treatment of cisplatin-induced renal injury. Acta Acad Med Xuzhou(徐州医学院学报), 2013, 33(7):488-490.
[36] KOMATSU H, YAGASAKI K, HIRATA K, et al. Unmet needs of cancer patients with chemotherapy-related hand-foot syndrome and targeted therapy-related hand-foot skin reaction: a qualitative study. Ur J Oncol Nurs, 2019, 38: 65-69.
[37] NIKOLAOU V, SYRIGOS K, SAIF M W. Incidence and implications of chemotherapy related hand-foot syndrome. Exp Opin Drug Saf, 2016, 15(12):1625-1633.
[38] BUN S, YUNOKAWA M, TAMAKI Y, et al. Symptom management: the utility of regional cooling for hand-foot syndrome induced by pegylated liposomal doxorubicin in ovarian cancer. Support Care Cancer, 2018, 26(7):2161-2166.
[39] SHI Y K, SUN Y. Manual of Medical Oncology(临床肿瘤内科手册). Beijing: People′s Medical Publishing House, 2015.
[40] QIAO J, FANG H. Hand-foot syndrome related to chemotherapy. CMAJ, 2012, 184(15):E818.
[41] INOKUCHI M, ISHIKAWA S, FURUKAWA H, et al. Treatment of capecitabine-induced hand-foot syndrome using a topical retinoid: a case report. Oncol Lett, 2014, 7(2):444-448.

基金

中国医学科学院临床与转化基金项目资助(2019XK320066)
PDF(6481 KB)

Accesses

Citation

Detail
段落导航
相关文章

/

〈 〉